THE IMPACT OF MEDICINAL PLANTS ON ASTHENIA, DYSPEPSIA, AND QUALITY OF LIFE IN REHABILITATION AFTER CHRONIC HEPATITIS C
DOI:
https://doi.org/10.55640/Keywords:
chronic hepatitis C, rehabilitation, medicinal plants, phytotherapy, asthenia, dyspepsia, quality of life, silymarin, post-viral fatigueAbstract
Chronic hepatitis C is now a curable infection for the vast majority of patients treated with direct-acting antivirals, yet clinical rehabilitation does not end with viral eradication. A proportion of patients continue to report asthenia, nonspecific dyspeptic complaints, reduced vitality, and an incomplete recovery of health-related quality of life after achieving sustained virologic response. This article reviews the possible role of medicinal plants as an adjunctive component of post-hepatitis C rehabilitation. The paper was prepared as a structured narrative review based on contemporary hepatology guidance, studies on patient-reported outcomes after antiviral therapy, and publications evaluating phytotherapeutic interventions relevant to fatigue, dyspepsia, and liver support. The available evidence indicates that most patients experience measurable improvement in quality of life after successful antiviral treatment; however, symptom persistence remains clinically important, particularly in those with advanced fibrosis, comorbidity, or psychosocial burden. Among medicinal plants, silymarin is the best studied in chronic hepatitis C, but oral formulations have not shown convincing benefits for virologic or biochemical endpoints. By contrast, plant-based combinations such as peppermint oil and caraway oil have more persuasive evidence for functional dyspeptic symptoms, although not specifically in post-hepatitis C populations. Evidence for phytotherapeutic relief of asthenia is promising but indirect, coming mainly from broader post-viral fatigue research. The modern conclusion is that medicinal plants may be considered only as individualized adjuncts within a rehabilitation program that also includes lifestyle counseling, nutritional correction, psychological support, and structured follow-up. They should not replace etiologic treatment, fibrosis surveillance, or standard symptom-oriented medical care.
Downloads
References
1.American Association for the Study of Liver Diseases, & Infectious Diseases Society of America. (2023, December 19). Monitoring patients who are starting HCV treatment, are on treatment, or have completed therapy. HCV Guidance. https://www.hcvguidelines.org/evaluate/monitoring
2.Reiberger, T., Lens, S., Cabibbo, G., Nahon, P., Zignego, A. L., Deterding, K., Elsharkawy, A. M., & Forns, X. (2024). EASL position paper on clinical follow-up after HCV cure. Journal of Hepatology, 81(2), 326-344. https://doi.org/10.1016/j.jhep.2024.04.007
3.Huang, R., Shang, J., Chen, H., Li, J., Xie, Q., Feng, J., Wei, L., & Rao, H. (2024). Sustained virologic response improved the long-term health-related quality of life in patients with chronic hepatitis C: A prospective national study in China. BMC Infectious Diseases, 24, 72. https://doi.org/10.1186/s12879-023-08940-3
4.Yi, C.-H., Bair, M.-J., Wang, J.-H., Wong, M.-W., Liu, T.-T., Lei, W.-Y., Liang, S.-W., Lin, L., Hung, J.-S., Huang, J.-F., Hsu, Y.-C., & Chen, C.-L. (2022). Improvement of patient-reported outcomes in patients achieving sustained virologic response with direct-acting antivirals for hepatitis C virus infection. Journal of Microbiology, Immunology and Infection, 55(4), 643-650.
5.Fagundes, R. N., Ferreira, L. E. V. V. de C., & Pace, F. H. de L. (2020). Health-related quality of life and fatigue in patients with chronic hepatitis C with therapy with direct-acting antivirals agents interferon-free. PLoS ONE, 15(8), e0237005. https://doi.org/10.1371/journal.pone.0237005
6.Guggisberg, H., Nicca, D., Kohler, A., Bruggmann, P., & Künzler-Heule, P. (2022). “Shaping the new freedom”: A reflexive thematic analysis on patients' post cure needs after years of living with hepatitis C. Swiss Medical Weekly, 152, w30177.
7.Fried, M. W., Navarro, V. J., Afdhal, N., Belle, S. H., Wahed, A. S., Hawke, R. L., Doo, E., Meyers, C. M., Reddy, K. R., & Silymarin in NASH and C Hepatitis (SyNCH) Study Group. (2012). Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: A randomized controlled trial. JAMA, 308(3), 274-282. https://doi.org/10.1001/jama.2012.8265
8.Freedman, N. D., Curto, T. M., Morishima, C., Seeff, L. B., Goodman, Z. D., Wright, E. C., Sinha, R., & HALT-C Trial Group. (2011). Silymarin use and liver disease progression in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis trial. Alimentary Pharmacology & Therapeutics, 33(1), 127-137. https://doi.org/10.1111/j.1365-2036.2010.04503.x
9.Yang, Z., Zhuang, L., Lu, Y., Xu, Q., & Chen, X. (2014). Effects and tolerance of silymarin (milk thistle) in chronic hepatitis C virus infection patients: A meta-analysis of randomized controlled trials. BioMed Research International, 2014, 941085. https://doi.org/10.1155/2014/941085
10.Li, J., Lv, L., Zhang, J., Xu, L., Zeng, E., Zhang, Z., Wang, F., & Tang, X. (2019). A combination of peppermint oil and caraway oil for the treatment of functional dyspepsia: A systematic review and meta-analysis. Evidence-Based Complementary and Alternative Medicine, 2019, 7654947. https://doi.org/10.1155/2019/7654947
11.Gwee, K.-A., Holtmann, G., Tack, J., Suzuki, H., Liu, J., Xiao, Y., Chen, M.-H., Hou, X., Wu, D.-C., Toh, C., Lu, F., & Tang, X.-D. (2021). Herbal medicines in functional dyspepsia—Untapped opportunities not without risks. Neurogastroenterology & Motility, 33(2), e14044. https://doi.org/10.1111/nmo.14044
12.Hu, L.-Y., Cai, A.-Q., Li, B., Li, Z., Liu, J.-P., & Cao, H.-J. (2024). Chinese herbal medicine for post-viral fatigue: A systematic review of randomized controlled trials. PLoS ONE, 19(3), e0300896. https://doi.org/10.1371/journal.pone.0300896
13.Ballotin, V. R., Bigarella, L. G., Brandão, A. B. M., Balbinot, R. A., Balbinot, S. S., & Soldera, J. (2021). Herb-induced liver injury: Systematic review and meta-analysis. World Journal of Clinical Cases, 9(20), 5490-5513. https://doi.org/10.12998/wjcc.v9.i20.5490
14.Chalasani, N., Bonkovsky, H. L., Fontana, R., Lee, W., Stolz, A., Talwalkar, J., Reddy, K. R., Watkins, P. B., Navarro, V., Barnhart, H., Gu, J., Serrano, J., & United States Drug Induced Liver Injury Network. (2023). Drug, herbal, and dietary supplement-induced liver injury: AASLD practice guidance. American Association for the Study of Liver Diseases. https://www.aasld.org/practice-guidelines/drug-herbal-and-dietary-supplement-induced-liver-injury
15.European Association for the Study of the Liver. (2019). EASL Clinical Practice Guidelines: Drug-induced liver injury. Journal of Hepatology, 70(6), 1222-1261. https://doi.org/10.1016/j.jhep.2019.02.014
Downloads
Published
Versions
- 2026-04-12 (2)
- 2026-04-12 (1)
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
Germany
United States of America
Italy
United Kingdom
France
Canada
Uzbekistan
Japan
Republic of Korea
Australia
Spain
Switzerland
Sweden
Netherlands
China
India
